Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

Eli Lil­ly has come out swing­ing at J&J, stak­ing out its chal­lenger po­si­tion in a crowd­ed bat­tle of plaque pso­ri­a­sis block­busters.

In a Phase IV head-to-head study with 1,027 pa­tients, Lil­ly says its IL-17A in­hibitor Taltz beat J&J’s IL-23/p19 drug Trem­fya on com­plete skin clear­ance at week 12 as de­fined by PASI 100. It’s the first di­rect com­par­i­son of these two class­es us­ing PASI 100 as a pri­ma­ry end­point, Lil­ly says, though it al­so shows that Taltz is con­sis­tent­ly su­pe­ri­or in mea­sures of PASI 50, PASI 75 and PASI 90 at mul­ti­ple (al­though not all) time points — com­pris­ing a num­ber of “key sec­ondary end­points.”

Lo­tus Mall­bris

The num­bers are re­served for fu­ture sci­en­tif­ic meet­ings and jour­nals. Mean­while, in­ves­ti­ga­tors are still track­ing and an­a­lyz­ing da­ta on the pro­por­tion of pa­tients main­tain­ing PASI 100 af­ter 24 weeks.

“Lil­ly’s goal is to raise the treat­ment bar for peo­ple liv­ing with pso­ri­a­sis,” said Lo­tus Mall­bris, vice pres­i­dent of im­munol­o­gy de­vel­op­ment. “And re­search shows that pa­tients want clear skin and rapid im­prove­ments.”

No­tably, J&J ran its own head-to-head against Cosen­tyx and her­ald­ed a win late last year for Trem­fya, which helped a high­er pro­por­tion of pa­tients achieve a 90% re­duc­tion in PASI scor­ing than No­var­tis’ dom­i­nant ri­val. Re­searchers said that 84.5% of the pso­ri­a­sis pa­tients tak­ing Trem­fya hit a PASI 90 score at 48 weeks, com­pared to 70% for Cosen­tyx.

Cosen­tyx, al­so an IL-17 drug, has ac­crued $1.6 so far this year. In com­par­i­son, Taltz — which was first ap­proved in 2016, a year lat­er than Cosen­tyx — has scored $606.5 mil­lion, while Trem­fya (ap­proved yet an­oth­er year lat­er) count­ed $452 mil­lion.

But the race is far from over. As the en­trance of new com­peti­tors and in­di­ca­tions com­pli­cate the pic­ture, Lil­ly will have to beat more than just J&J, which al­so has Ste­lara in its ar­se­nal. Ab­b­Vie is now in the pso­ri­a­sis game, look­ing for a come-from-be­hind win with Skyrizi. And Taltz still has a long way to prov­ing it­self in pso­ri­at­ic arthri­tis as well as non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis, a key are­na Lil­ly is an­gling to en­ter.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.